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Abstract 1 
Early diagnosis in Alzheimer's disease (AD), prior to the appearance of marked clinical 2 
symptoms, is critical to prevent irreversible neuronal damage and neural malfunction that leads 3 
to dementia and death. Therefore, there is an urgent need to generate new contrast agents which 4 
reveal by a non-invasive method the presence of some of the pathological signs of AD. 5 
In the present study we demonstrate for the first time a new nanoconjugate composed of 6 
magnetic nanoparticles bound to an anti-ferritin antibody, which has been developed based on 7 
the existence of iron deposits and high levels of the ferritin protein present in areas with a high 8 
accumulation of amyloid plaques (particularly the subiculum in the hippocampal area) in the 9 
brain of a transgenic mouse model with five familial AD mutations.  10 
Both in vitro and after intravenous injection, functionalized magnetic nanoparticles were able to 11 
recognize and bind specifically to the ferritin protein accumulated in the subiculum area of the 12 
AD transgenic mice. 13 
Keywords 14 
Iron oxide nanoparticles, nanoconjugates, ferritin, iron deposits, microglia, Alzheimer´s disease. 15 
Introduction 16 
Alzheimer´s disease (AD) is a progressive neurodegenerative disorder, with no known 17 
prevention or cure, which affects approximately 47 million patients worldwide1. At present, a 18 
definitive diagnosis of AD is only possible after the patient's death, when the presence of 19 
amyloid plaques and tangles in the brain parenchyma can be revealed by histological 20 
examination2. Current diagnostic practices, including assessments of clinical history to detect 21 
changes in behavior, physical examination, neuropsychiatric testing (Mini-Mental State 22 
Examination, MMSE), diagnostic laboratory tests and neuroimaging, can only make a 23 
"probable" diagnosis of AD3. 24 
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To date, the best-established biomarkers for the detection and monitoring of AD include 1 
measures of ß amyloid peptide and tau in cerebrospinal fluid, hippocampal atrophy as assessed 2 
by magnetic resonance imaging (MRI), reduction in the rate of glucose metabolism in the brain, 3 
assessed by positron emission tomography (PET) with fluorodeoxyglucose, and brain 4 
accumulation of ß amyloid peptide visualized by PET using Pittsburgh Compound B3,4. None of 5 
these methods, alone or in combination, provide high accuracy in the early diagnosis of 6 
pathology. Therefore, great emphasis has been placed on the search for biomarkers indicative of 7 
AD, but most attempts to date have had limited success5. 8 
With the improvements in imaging technologies in recent years, there has been a growing 9 
interest in developing methods to visualize amyloid plaques in AD, especially in transgenic 10 
mice, using methods that could eventually be applied to humans6,7. The therapeutic approaches 11 
currently developed show that the available therapies are more effective when applied at very 12 
early stages, when a low burden of amyloid plaques can be detected8,9.Therefore, early 13 
diagnosis of the disease is a critical issue. 14 
MRI has a higher spatial resolution than PET in the study of whole brain. MRI is a widely 15 
available technique that can produce images in both experimental animals and in patients 16 
without the need for a radiotracer10. Several groups have been able to visualize amyloid plaques 17 
in vivo utilizing both the endogenous contrast induced by the plaques attributed to their iron 18 
content and by selectively enhancing the signal from amyloid plaques using molecular-targeting 19 
vectors labeled with MRI contrast agents11,12. These data were corroborated using both 20 
postmortem brain tissue from AD patients13, and brain tissue from transgenic AD mice14,15,16. 21 
Histological findings associated with AD show the presence of iron deposits in the vicinity of 22 
plaques in the brains of patients with the disease17,18. The intrinsic MRI contrast arising from the 23 
iron associated with plaques creates an unexpected opportunity for the noninvasive investigation 24 
of the temporal course of development of the plaques in the animal brain, thus reducing 25 
intersubject variability16. However, the limiting factor of this methodological approach, in 26 
which no contrast agent is used, is that only amyloid plaques with a diameter of more than 50 27 
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µm can be detected, using acquisition times that generally exceed 2h. These very long times 1 
complicate the acquisition of in vivo images, not only in research animals, but also in the 2 
clinical setting. 3 
In order to detect amyloid plaques at early stages of the disease, and to diminish the acquisition 4 
times of in vivo imaging, several studies have proposed the use of magnetic iron oxide 5 
nanoparticles as specific contrast agents for MRI19,20. The hypointense effect exhibited by these 6 
particles in T2 and T2* image sequences provides greater contrast in MR images. Therefore, the 7 
use of magnetic iron oxide nanoparticles (MNPs) may be a good method for the early diagnosis 8 
of AD. 9 
Different types of functionalized MNPs have been evaluated in AD models including those 10 
coupled to amyloid Β peptide 1–4021, amyloid Β peptide 1–3022, amyloid Β peptide 1–4211 and 11 
to peptides highly specific for Aβ amyloid fibrils23,24; also by coupling the MNPs to antibodies 12 
which specifically recognize amyloid B peptide 1–42 as a component of amyloid 13 
plaques25,26,27,19. MNPs functionalized with different markers of amyloid plaques, such as 14 
Thioflavin S28, Congo Red29, 1,1-dicyano-2-[6-(dimethylamino)naphthalene-2-yl] propene 15 
(DDNP)30 and curcumin31, have also been used to target and detect amyloid plaques in AD 16 
transgenic mice using ex vivo MRI with long acquisition times.  17 
The localized iron accumulation and formation of iron deposits in the brain, together with 18 
changes in the regulation of iron–storage and the association of iron with several proteins is 19 
evident in several neurodegenerative diseases, including AD32,33. Proteomic analysis has also 20 
shown higher levels of ferritin, the main protein that stores and transports iron in vertebrates, in 21 
the hippocampal region of AD patients compared to healthy individuals34. Moreover, iron and 22 
ferritin are deposited in close proximity to amyloid plaques in the cerebral cortex of AD 23 
patients, as determined in post-mortem specimens35,36. 24 
The present manuscript presents a novel nanoconjugate based on MNPs bound to an anti-ferritin 25 
antibody, which could be a useful tool to detect increases in the expression of ferritin in the 26 
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brain parenchyma of transgenic mice with five familial Alzheimer’s disease mutations 1 
(5XFAD) by MRI37. This nanoconjugate showed a high specific binding to the ferritin protein 2 
present in the subiculum of 5XFAD mice after being injected intravenously, while non-3 
functionalized MNPs could not be detected in the same brain region after injection. The results 4 
demonstrated that the functionalization of MNPs with the anti-ferritin antibody generated a 5 
specific contrast agent useful for detecting the presence of ferritin in the brain parenchyma of 6 
the 5XFAD mice, and consequently the presence of iron deposits in the vicinity of amyloid 7 
plaques, one of the hallmarks of AD. 8 
Results and Discussion 9 
We report here a novel method for the selective marking of the protein ferritin, present in areas 10 
with a high accumulation of amyloid plaques, with functionalized magnetic nanoparticles. This 11 
novel nanoconjugate, which selectively marked ferritin, might be used in the near future as a 12 
contrast agent for MRI enabling the noninvasive early detection of AD.  13 
The development of biofunctionalized devices could become a useful tool in diagnosis and 14 
therapy of several neuropathologies and become a strategy to deepen knowledge in cell biology 15 
and histopathology in neuroscience. 16 
Iron and ferritin accumulation in 5XFAD mice 17 
There is some evidence for altered iron metabolism in AD, including alterations in iron 18 
accumulation and changes in transferrin and ferritin levels17. Striking iron accumulation has 19 
been closely associated with amyloid plaques, neurofibrillary tangles, and neuropil threads in 20 
clinical cases of AD38. Increased levels of ferritin have also been observed by proteomic 21 
analysis within the hippocampal region in AD patients compared to healthy individuals34. To 22 
determine whether these highly relevant histological findings were also present in 5XFAD mice, 23 
the presence of iron was evaluated in 9-month-old 5XFAD transgenic and nontransgenic mice 24 
by Prussian blue staining. Brain sections from nontransgenic mice showed no obvious Prussian 25 
blue staining, indicating a lack of iron accumulation in the brain (Figure 1A). However, iron 26 
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burden was obvious in the subiculum of 5XFAD mice (Figure 1B), an area usually containing a 1 
high number of amyloid plaques37. In fact, when brain sections were stained with Thioflavin S, 2 
a marker of amyloid plaques, a strong signal could be detected in the subiculum area only in the 3 
5XFAD mice (Figure 1D), indicating a high density of amyloid plaques coinciding with the 4 
strong accumulation of iron in this hippocampal region. As expected, amyloid protein was not 5 
detected in nontransgenic mice (Figure 1C). 6 
Since high iron content was observed in 5XFAD mice in the hippocampal area, we stained 7 
similar brain sections with an anti-ferritin antibody to determine the levels of this iron-binding 8 
protein in this region. While the presence of this protein in control mice was almost negligible 9 
(Figure 1E), in 5XFAD brain sections, strong labeling for ferritin protein was evident in the 10 
subiculum (Figure 1F). 11 
This high expression of ferritin in the subiculum of the 5XFAD transgenic mice coincided 12 
perfectly with the presence of a high number of amyloid plaques in the same area (arrows in 13 
Figure 1D and 1F). 14 
The regional accumulation of iron deposits in the brain, together with changes in the regulation 15 
of iron storing proteins and the association of iron with neuropathology is evident in several 16 
neurodegenerative diseases, including AD , Parkinson's disease, multiple sclerosis and 17 
Huntington's disease, where the accumulation of iron in the brain corresponds to the regions of 18 
greatest neuronal degeneration39-44. Iron accumulation in these neurodegenerative diseases 19 
occurs in different brain regions. In AD, iron accumulation occurs in the hippocampus40. In 20 
Huntington's disease, an increased iron burden in the cortex and striatum has been shown in 21 
both patients and transgenic mouse models for the disease41. In patients with Parkinson's 22 
disease, accumulation of iron occurs in the substantia nigra42. In the case of multiple sclerosis, 23 
an increase in iron in the spinal cord white matter has also been described43. Therefore, a 24 
specific contrast agent able to detect iron deposits by MRI could be useful for the diagnosis of 25 
several neurodegenerative diseases. Furthermore, each neurodegenerative disorder could then be 26 
distinguished by determining the brain area(s) where such iron accumulations occur. In this 27 
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way, the developed nanoconjugate would be a useful tool to detect AD, depending on the 1 
location of the iron accumulations in the brain. 2 
Iron deposits and a strong immunoreactivity for ferritin have been observed near the amyloid 3 
plaques in the cortex and in the hippocampus of AD patients35,36. Ferritin accumulation was 4 
almost exclusively associated with reactive microglial cells, which appeared to have greatly 5 
proliferated36. To determine if iron and ferritin accumulations in 5XFAD mice were deposited 6 
close to the amyloid plaques, a double staining was performed using an antibody specific for the 7 
ferritin protein and a specific marker for amyloid plaques (Thioflavin S). Cells labeled with the 8 
anti-ferritin antibody were found near the amyloid plaques, with their processes in close contact 9 
with and surrounding the plaques in 5XFAD brains (Figure 2). In brain slices obtained from AD 10 
patients, astrocytes and microglia have been shown to be associated with the amyloid plaques, 11 
where they show an activated, amoeboid state surrounding the plaques with their processes44,45. 12 
In the case of 5XFAD mice, staining with the astrocytic marker for glial fibrillary acidic protein 13 
(GFAP) showed a high number of GFAP-positive cells throughout the subiculum with no 14 
colocalization with ferritin positive cells (Figure 3C). However, the selective labeling of 15 
microglial cells using tomato lectin, a protein with specific affinity for poly-N-acetyl 16 
lactosamine sugar residues that are found on the plasma membrane and in the cytoplasm of 17 
microglia, established a high colocalization of this marker with ferritin (Figure 3D). These 18 
results indicate that microglial cells colocalized with ferritin and were abundant in areas 19 
showing a high density of ferritin and amyloid plaques (Figures 3A and 3B, respectively). 20 
Previous studies suggested that in the brain of patients with AD, the enhanced ferritin 21 
expression indicated microglia degeneration instead of reflecting an activated state45,46. The 22 
enhanced expression of ferritin protein has been described to increase the susceptibility of 23 
microglia to degeneration, particularly in the aging brain45. Senescent microglia may be less 24 
efficient in maintaining iron homeostasis, and free iron could promote oxidative damage in 25 
neurodegenerative diseases. Therefore, in brains affected by AD, increased expression of ferritin 26 
could constitute a marker of microglial degeneration. 27 
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These results indicate that the increased presence of ferritin in AD brains could serve as an 1 
interesting biomarker to reveal the presence and localization of amyloid plaques. Therefore, 2 
conjugation of an anti-ferritin antibody with magnetic nanoparticles could produce a specific 3 
contrast agent useful for noninvasively detecting the presence of amyloid plaques in the brain 4 
using MRI. 5 
Coupling of the anti-ferritin antibody to MNPs 6 
An anti-ferritin polyclonal antibody was immobilized onto 50nm dextran-coated MNPs as 7 
described in the methods section. A polyclonal antibody that recognizes multiple epitopes on 8 
the same antigen was chosen due to its high affinity and tolerance to possible changes in the 9 
antigen47. The preparation of the nanoconjugates was based on the carbodiimide method48, 10 
leading to the formation of a very stable complex. The efficiency of the antibody binding to the 11 
MNPs was determined by a dot-blot assay (Figure 4). Dot-blot analysis confirmed a high level 12 
of anti-ferritin antibody binding to MNPs, since only small traces of free anti-ferritin antibody 13 
were detected in the unbound fraction (Figure 4C); a high amount of anti-ferritin antibody 14 
present at the beginning of the coupling reaction (Figure 4A) could be detected conjugated to 15 
the MNPs in the MNPs-anti-ferritin fraction (Figure 4B) after the coupling reaction. Therefore, 16 
the binding of the anti-ferritin antibody to the MNPs to form the MNP-anti-ferritin conjugate 17 
was highly effective.  18 
These previous results were also confirmed by protein quantification using an improved 19 
Bradford protein assay permitting quantification of low protein concentrations49. The binding 20 
efficiency was estimated to be about 30 ± 14 molecules of anti-ferritin bound per nanoparticle. 21 
Binding of the antibody to the MNPs may increase the final hydrodynamic diameter of the 22 
MNPs as previously described for similar MNPs50 in which the antibody bound to the MNPs 23 
increased twofold their final hydrodynamic diameter. 24 
Cell viability after incubation with MNPs 25 
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To discard a potential neurotoxicity of the MNPs, we determined that the incubation of human 1 
neuroblastoma SH-SY5Y cells with MNPs and MNPs-anti-ferritin was feasible and did not 2 
impair cell viability in vitro. SH-SY5Y cells were incubated with both types of MNPs and 3 
tested for viability using doses up to 200 µg/mL and incubation times of 72 hours, which did not 4 
significantly affect neuroblastoma cells survival, as evaluated by the lactate dehydrogenase 5 
(LDH) activity assay (Figure 5A). Once determined that MNPs did not induce a loss of cell 6 
viability on SHSY5Y cell line, we analyzed the effect of MNP and MNPs-anti-ferritin on 7 
primary cell cultures obtained from mouse brains, in order to discard an effect of the MNPs on 8 
some specific type of brain cells (i.e.,neurons, astrocytes, or microglial cells). The results 9 
showed that cell viability rates were similar in control and MNPs-treated cell cultures (Figure 10 
5B) and that the number of neurons and astrocytes did not decrease in the presence of MNPs or 11 
MNPs-anti-ferritin with respect to untreated control cells (Figure 5C). The number of microglia 12 
cells stained with the anti-Iba1 antibody were higher in MNPs-treated cells compared to 13 
untreated control cells (in which no microglial cells were detected), indicating that MNPs were 14 
preferentially taken up by the microglial cells (Figure 5D), although the viability of the cells 15 
during the periods of time analyzed was not affected. 16 
These results suggested that although iron oxide nanoparticles could induce oxidative stress51, 17 
the levels of intracellular iron accumulation resulting from the incubation with MNPs and the 18 
presence of the antibody in the case of the nanoconjugate MNP-anti-ferritin, did not induce 19 
acute cell toxicity at the times and concentrations analyzed. In addition, Mahmoudi and 20 
coworkers52 have shown that the interaction of nanoparticles with serum proteins forming the 21 
nanomaterial´s protein corona inhibits the formation of Aβ fibril upon their entrance to the 22 
biological medium. 23 
In vitro specificity of the MNP-anti-ferritin conjugate 24 
To verify the in vitro specificity of the MNP-anti-ferritin conjugate, fixed brain sections from 9-25 
month-old 5XFAD and nontransgenic mice, with a high (Figure 6A) and low (Figure 6E) 26 
expression of ferritin, respectively, were incubated with the MNP-anti-ferritin conjugate. The 27 
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presence of the MNP-anti-ferritin conjugate bound to the subiculum in brain slices was detected 1 
using an anti-rabbit-Cy3 antibody which recognized only the polyclonal ferritin antibody bound 2 
to the MNPs. The results indicated a strong binding in the case of 5XFAD mice (Figure 6B and 3 
6C) and a nearly absent, undistinguishable from background, binding in nontransgenic mice 4 
(Figure 6F and 6G). The accumulation of MNPs in the slices could even be observed by 5 
transmission light microscopy as highly localized and crowded black dots in 5XFAD (Figure 6 
6D). This type of signal was undetectable in nontransgenic mice (Figure 6H). 7 
As evidenced in Figure 6, the accumulation of the MNP-anti-ferritin conjugate in the subiculum 8 
is higher in 5XFAD than in nontransgenic brain sections (compare Figure 6 B–D with panels F–9 
H). The binding of MNP-anti-ferritin conjugate colocalized with cells showing clear-cut, high 10 
expression of ferritin in 5XFAD (Figure 6A) in comparison with nontransgenic (Figure 6E) 11 
mice. 12 
Also, the accumulation of bound MNP-anti-ferritin conjugate in the subiculum of 5XFAD mice 13 
regionally correlates with the presence of amyloid plaques and ferritin in the subiculum, 14 
previously shown in Figure 1D and 1F, respectively. As expected, in brain sections from 15 
nontransgenic mice (Figure 6F–H), very few MNP-anti-ferritin nanoconjugate could be detected 16 
(Figure 6G), and the black stain observed by transmission light microscopy was absent (Figure 17 
6H), consistent with the very weak expression of ferritin in the subiculum of nontransgenic mice 18 
(Figure 6E). 19 
Consequently, these results indicated that the MNP-anti-ferritin conjugate specifically binds and 20 
detects the enhanced expression of the ferritin protein that occurs in the subiculum of 9-month-21 
old 5XFAD mice in vitro. 22 
In vivo specificity of the MNP-anti-ferritin conjugate 23 
Once the in vitro specificity of the MNP-anti-ferritin nanoconjugate was confirmed in fixed 24 
5XFAD brain sections, its efficiency was tested in vivo after intravenous injection in 5XFAD 25 
mice. Since the previous in vitro results indicated the absence of detectable signal in control 26 
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animals, wild type mice were not used in these experiments to reduce the number of animals 1 
used in adherence to the 3Rs principles. Plain non-functionalized MNPs and MNP-anti-ferritin 2 
conjugates were intravenously injected into the retro-orbital sinus of 5XFAD mice. Six hours 3 
after intravenous administration of the MNPs, 5XFAD brains were fixed and subsequently 4 
analyzed by histological analyses to localize the final distribution of the MNPs. The 5 
accumulation of ferritin protein and amyloid plaques in the subiculum of transgenic mice was 6 
again confirmed using an anti-ferritin antibody and Thioflavin-S staining, respectively (Figure 7 
7A). Serial sections were stained with the secondary polyclonal Cy3-antibody alone to detect 8 
the presence of the MNP-anti-ferritin conjugates in the subiculum of 5XFAD mice previously 9 
injected with the nanoconjugate (Figure 7B). Moreover, the MNPs were fluorescently labeled 10 
using an antibody against their coating (antidextran-FITC; Figure 7D and 7G). The results 11 
shown in Figure 7 demonstrate that the MNP-antiferritin nanoconjugates injected intravenously 12 
accumulate in the subiculum area of the transgenic 5XFAD brains, where a high number of 13 
amyloid plaques and an enhanced expression of ferritin exist (Figure 7A–E). In contrast, when 14 
non-functionalized MNPs were injected intravenously in 5XFAD mice, only very few, 15 
occasional, MNPs could be detected in the subiculum area (Figure 7 F–H), demonstrating a high 16 
specificity of the MNP-anti-ferritin conjugates to reveal the accumulation of ferritin in the brain 17 
of living 5XFAD mice. These results also indicated that non-functionalized MNPs did not bind 18 
to 5XFAD brain parenchyma in a non-specific manner after intravenous injection, 19 
demonstrating a lack of nonspecific binding of the non-functionalized MNPs to the iron deposits 20 
found in the subiculum of 5XFAD mice. Moreover, the robust colocalization (Figure 7E) of the 21 
ferritin antibody signal (Figure 7C) and the MNPs (Figure 7D) indicated that the MNP-anti-22 
ferritin nanoconjugate was highly stable under physiological in vivo conditions, avoiding 23 
potential opsonization when circulating through the bloodstream and eluding clearance by the 24 
reticuloendothelial system before reaching its target. 25 
The ferritin protein also circulates in the plasma, where it transports iron. Ferritin in plasma has 26 
been shown to enter the brain parenchyma through the blood brain barrier (BBB) using the 27 
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ferritin H receptor present on the plasma membrane of endothelial cells that form the BBB53,54. 1 
Therefore, a theoretical drawback of the present method would be that it might be possible that 2 
plasmatic ferritin could saturate all the antibody recognition sites available on the MNPs, thus 3 
preventing the binding of the nanoconjugate to the ferritin present in the brain parenchyma. This 4 
would seriously limit the efficacy of the iron-ferritin detection method, and its potential use as a 5 
diagnostic tool. Although we cannot exclude some binding to plasma ferritin, our results 6 
indicate that the MNP-anti ferritin conjugate has enough free binding sites to recognize the 7 
ferritin accumulated in the subiculum of 5XFAD mice. 8 
Based on our results, we propose that the MNPs conjugated to anti-ferritin antibody could be a 9 
useful tool for the imaging and detection of iron accumulations in the brain parenchyma of AD 10 
patients. Future work will be needed to increase the binding capacity and affinity of the 11 
nanoconjugate. A limitation of our method is the need to open the BBB with the use of 12 
mannitol. 13 
Although intravenous mannitol injection has been used safely in patients under a variety of 14 
clinical settings55, a potential future clinical use of this contrast agent would require further 15 
modifications including the coupling of MNPs with specific proteins actively transported into 16 
the brain22 or their PEGylation11 in order to increase the ability of the MNPs to cross the BBB 17 
and avoid the use of mannitol.  18 
Ex vivo brain MRI 19 
After confirming that MNP-anti-ferritin nanoconjugate injected intravenously specifically 20 
bound to the subiculum region in transgenic 5XFAD brains, MR images from the same area 21 
were acquired from a different set of experimental animals after the injection of non-22 
functionalized and functionalized MNPs as a preliminary study. Nontransgenic mice injected 23 
with MNP-anti-ferritin and 5XFAD mice without MNPs did not show any non-specific marks in 24 
MR images (data not shown). Although there were no evident marks on MR images of the 25 
injected MNPs (Figure 8 A and 8B), a significant decrease in T2* value in both the right and 26 
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left hippocampus was found in 5XFAD animals injected with functionalized MNPs as 1 
compared to 5XFAD mice injected with non-functionalized MNPs (Figure 8 C). Therefore, 2 
changes in T2* value in MNP-anti-ferritin injected 5XFAD mice could be attributed to ferritin 3 
accumulation and consequently to amyloid plaque deposition in the transgenic mice, as 4 
previously demonstrated by histological analysis (Figure 7). Therefore, our results are consistent 5 
with the literature. Yang et al56 also reported a decrease of T2* value in the hippocampus after 6 
nanoparticle administration in both in vivo and ex vivo MRI studies. 7 
In order to increase the binding of the nanoconjugate MNPs-anti-ferritin to the transgenic mouse 8 
brains, higher amounts of anti-ferritin antibody could be used for the coupling reaction. 9 
Moreover, the dosage we used of MNP-anti-ferritin at 20 µmol Fe3O4/kg body weight is far 10 
from the range of preclinical MRI applications for which contrast agents are typically injected 11 
intravenously by femoral or tail vein, at 200 µmol Fe3O4/kg body weight for diagnostic 12 
purposes11,29 and similar to the doses of commercial MNPs (i.e., Endorem®, Resovist®, or 13 
Feridex®) used in clinical trials (15µmol Fe3O4/kg body weight). Therefore, since no 14 
cytotoxicity of the MNPs used to synthesize the nanoconjugate was observed even at the highest 15 
concentration used (Figure 5), a higher dose of MNPs could be injected in vivo to induce 16 
qualitative changes on brain MRI allowing visual ferritin accumulation in the future. 17 
The specificity of this nanoconjugate is important because, to date, the detection of iron deposits 18 
associated with AD by MRI is only possible when a high concentration of iron is deposited 19 
around the amyloid plaques12, preventing early diagnosis of the disease. The use of contrast 20 
agents like the one described here, based on MNPs functionalized with antibodies directed 21 
against the protein that stores iron, would allow an earlier detection of the accumulation of 22 
ferritin and, hence, of iron, as we have shown in the present work. This would allow an early 23 
diagnosis of the disease, since the presence of iron deposits in the brains of patients with AD is 24 
one of the most common histopathological features associated with the disease17. Iron is known 25 
to promote aggregation of β-amyloid peptide and therefore a large number of therapeutic trials 26 
are currently aimed at reducing elevated levels of iron in the brains of AD patients57. Thus, an 27 
Page 13 of 42
ACS Paragon Plus Environment
ACS Chemical Neuroscience
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
14 
 
effective method for early and sensitive detection of iron levels in the brains of AD patients is 1 
necessary. 2 
These preliminary results of detecting ferritin accumulation in 5XFAD mice show a potential 3 
future high-specificity tool for diagnosis of Alzheimer’s disease. 4 
Methods 5 
Animals 6 
Hemizygous 5xFAD mice obtained from the Jackson Laboratory were used as a model of 7 
Alzheimer´s disease37. These 5xFAD mice carry five mutations associated with familial AD 8 
(Swedish (K670N, M671L), Florida (I716V) and London (V717I) mutations in amyloid 9 
precursor protein (APP) and M146L and L286V mutations in presenilin 1 (PS1)) and develop 10 
several features of AD described in humans, such as the presence of amyloid plaques, which 11 
appear as early as 2 months of age in these mice37. N=3 Nine month old male 5XFAD 12 
transgenic mice and n= 3 their wild-type (nontransgenic) littermates were used for all 13 
experiments as proof of concept to determine the specificity of the nanoconjugate. All 14 
procedures involving the use of animals were reviewed and approved by the local Animal Care 15 
Committee (Universidad Politécnica de Madrid) according to the guidelines of the European 16 
Community (ECC/566/2015). 17 
Histological analysis 18 
5XFAD and nontransgenic mice (9-month old) were anesthetized with an overdose of chloral 19 
hydrate and intracardially perfused with freshly prepared 4% paraformaldehyde (in 0.1 M 20 
phosphate buffer, pH 7.4). Brains were removed, postfixed for 12 h in the same fixative at 4 °C, 21 
and dehydrated in 30% sucrose solution at 4 °C until sunk. Thirty-µm thick coronal sections 22 
were collected using a freezing microtome (Leica SM 2400). 23 
Prussian blue iron staining was used to visualize the iron deposits in the brain sections of 24 
5XFAD and nontransgenic mice58. A previous inactivation of endogenous peroxidase activity in 25 
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the tissue was performed by incubating the sections in 3% H2 O2 and 10% methanol in 1 
phosphate buffered saline (PBS); samples were maintained at room temperature in the dark with 2 
shaking for 30 minutes. After rinsing with PBS, sections were incubated in the Prussian blue 3 
solution (2% potassium ferrocyanide trihydrate (Sigma # P-3289), 2% HCl, 1% Triton X-100 in 4 
distilled H2O) for 30 minutes. Samples were then washed twice in distilled H2O and treated with 5 
a solution of Ni-DAB (5mg of 3, 3'-diaminobenzidine (Sigma), 35 µL of 8% NiCl2 and 4 µL of 6 
30% H2 O2 in 10 mL of PBS) for 15 minutes. Sections were rinsed in PBS and mounted onto 7 
gelatinized glass slides (Menzel-Glaser). The slides were dried overnight, successively 8 
dehydrated with ethanol, delipidated with xylene and coverslipped with DPX mounting 9 
medium. 10 
Thioflavin S was used for the specific staining of amyloid plaques in brain sections from 11 
5XFAD mice49,59. Brain sections from 5XFAD and nontransgenic mice were mounted onto 12 
polylysine- treated slides (Thermo Scientific) and allowed to dry for 48h. Sections were then 13 
incubated in 0.05% Thioflavin-S (Sigma) diluted in 50% ethanol for 30 minutes, protected from 14 
light. After the incubation, sections were rinsed twice in 50% ethanol and once in distilled H2O. 15 
The slides were dried overnight and coverslipped with Mowiol mounting medium. 16 
Immunohistochemistry 17 
Thirty-µm serial sections obtained from 5XFAD and nontransgenic mice were also assessed by 18 
immunohistochemistry using a polyclonal antibody against ferritin (1:1000; Sigma) and a 19 
monoclonal antibody against GFAP (1:1000; Sternberger). Briefly, free-floating sections were 20 
incubated overnight at 4 °C with the primary antibodies diluted in PBS with 2% nonspecific 21 
serum. Sections were rinsed four times in PBS for a total time of 1 h and then incubated for 2 h 22 
with the secondary antibodies diluted in PBS (anti-mouse or anti-rabbit Cy3- conjugated 23 
antibodies, 1:200, all from Jackson Immunoresearch). Streptavidin-FITC (1:300; Vector Labs) 24 
was used to detect biotinylated Lectin (1:500; Sigma) for microglial cell staining. Brain sections 25 
were mounted onto gelatinized glass slides (Menzel-Glaser). The slides were dried overnight 26 
and coverslipped with Mowiol.  27 
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Preparation of MNP-anti-ferritin nanoconjugate 1 
MNP-anti-ferritin conjugates were prepared according to the carbodiimide method48. Briefly, 1 2 
mg of 50nm in diameter Fe3O4-dextran coated MNPs with a magnetite content of 35% (w/w) 3 
and functionalized with -COOH groups (Kisker # PMC-50) were washed with 0.1 M 2-(N-4 
morpholino)ethanesulfonic acid (MES) buffer at pH 5.5 and diluted to a final volume of 500 µL 5 
in MES buffer containing 20 mg of freshly prepared 1-ethyl-3-(3-dimethylaminopropyl) 6 
carbodiimide (EDC) and 40 mg of sulfo-N-hydroxysuccinimide (NHS). The particles were 7 
mixed on a shaker for 2 h at room temperature. After incubation, the particles were washed 8 
twice with 1 mL MES buffer at pH 5.5 and the activated particles were resuspended in 0.5 mL 9 
MES buffer at pH 5.5. Amine group-containing ligands (150 µg of a polyclonal anti-ferritin 10 
human antibody. Sigma-Aldrich Cat. No. F5012) were added to the activated particles and the 11 
suspension was mixed on a shaker overnight at room temperature. The conjugate was washed 12 
three times with 1 mL PBS, centrifuged each time at 5000 rpm for 5 minutes, resuspended in 13 
0.5 mL of PBS, and kept at 4 ºC until use. 14 
Dot-blot assay 15 
To test the efficiency of the coupling reaction of the anti-ferritin antibody to the MNPs, 1 µL 16 
drops of each solution used in the preparation of the MNP-anti-ferritin conjugate (anti-ferritin 17 
antibody, MNPs alone, medium containing unbound anti-ferritin antibody, and MNP-anti-18 
ferritin conjugate) were deposited onto a nitrocellulose membrane strip (Bio-Rad). After drying 19 
at room temperature, dot-blots were blocked for 1hour at room temperature with 5% skim milk 20 
in Tris-buffered saline (500 mM NaCl in 20 mM Tris, pH 7.4) containing 0.05% Tween 20 21 
(TTBS) and then incubated with a goat anti-rabbit peroxidase-conjugated antibody (1:5000; Life 22 
Technologies) for 1hour at room temperature. Immunoreactivity was detected using the ECL 23 
Western blotting detection system (Amersham Biosciences). In addition, protein concentrations 24 
in the coupling reaction (total and unbound antibody) were determined by an improved 25 
Bradford protein assay permitting quantification of low protein concentrations60, in order to 26 
confirm dot-blot results. The number of anti-ferritin molecules was calculated as previously 27 
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described61. In both assays, a control was performed to discard the precipitation of the antibody 1 
during the coupling reaction. 2 
Cell viability assays 3 
Human neuroblastoma cells (SH-SY5Y; ECACC No. 94030304) were maintained in DMEM 4 
medium supplemented with 10% heat-inactivated fetal bovine serum, 2mM L-glutamine, 5 
0.1mM nonessential amino acids, 100U/mL penicillin and 100 mg/mL streptomycin (Life 6 
Technologies). The cell line was maintained at 37ºC in a humidified incubator of 5% CO2: 95% 7 
air and passaged twice per week. For the cell viability assay, cells were plated on 96 well plates 8 
(15x103 cells/well, in triplicate for each condition). Twenty four hours after plating, the cells 9 
underwent treatment with MNPs and MNPs-anti-ferritin. Cell viability was evaluated 72 hours 10 
after the incubation with the MNPs by the LDH assay, using the Cytotoxicity Detection kit 11 
(Roche) and following the manufacturer’s instructions. Briefly, after the incubation time with 12 
the MNPs, cells were rinsed in PBS and lysed with 1% Triton X-100. Lysate was then collected 13 
after centrifugation at 1500 rpm for 5 minutes to remove cell debris. Cell-free supernatants were 14 
incubated with the kit´s substrate mixture. LDH activity was determined in a coupled enzymatic 15 
reaction; during this reaction, the tetrazolium salt is reduced to formazan. The formazan dye was 16 
quantified spectrophotometrically at 490 nm. LDH activity present in the medium was 17 
expressed as a percentage of the maximum activity, considering 100% of LDH activity released 18 
to the medium as the absorbance obtained when control cells (cells without MNPs) were lysed 19 
with 1% Triton X-100. 20 
Cortical mixed neuronal and glial cell cultures were prepared from 18-day-old BCL56 embryos 21 
as previously described62. Cerebral cortices were enzymatically dissociated in PBS containing 22 
1% bovine serum albumin, 0.4 mg/ml papain, and 6 mM glucose. Dissociated cells were 23 
collected by centrifugation (800 x g, 5 minutes) and resuspended in medium supplemented with 24 
20% horse serum. Culture medium consisted of Neurobasal with 1% glutamax-I and B27 25 
supplements (all from Gibco). The cells were then plated at 1x105 cells/cm2 on plastic plates 26 
pretreated for 1 day with 10 mM poly-L-lysine and for 2 hours with laminin (1 mg/ml). The 27 
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medium was replaced after 1 day by Neurobasal with 1% glutamax-I and B27 supplements. 1 
Two-thirds of the medium were replaced every second day. Cell cultures were maintained for 7 2 
days and then MNPs and MNPs-anti-ferritin were added at 200µg/mL for 3 days. To visualize 3 
the final location of MNPs in cortical cell cultures, red fluorescent MNPs (Chemicell nano-4 
screenMAG/R) were used (Figure 5D). Cells were then fixed in 4% paraformaldehyde and 5 
immunofluorescence was performed using the following primary antibodies: anti-β-III-tubulin 6 
(Sigma) to stain neurons, anti-GFAP (Sigma) to stain astrocytes, and anti-Iba-1 (Sigma) to label 7 
microglial cells. Cell nuclei were counterstained with Hoechst 33258 (Molecular Probes). For 8 
the cell viability assay, cells were plated on 96-well plates (15 x 103 cells/well, in triplicate for 9 
each condition). Twenty-four hours after plating, the cells underwent treatment with MNPs and 10 
MNPs-anti-ferritin. Cell viability was evaluated 72 hours after the incubation with the MNPs by 11 
using the Cell Proliferation Assay kit (AppliChem) following manufacturer instructions. This 12 
employs 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide salt (XTT). 13 
In living cells, mitochondria have the capability to reduce XTT to form an orange-colored, 14 
water-soluble dye63. Therefore, the concentration of this dye is proportional to the number of 15 
metabolically active cells. The absorbance of each well was measured spectrophotometrically at 16 
450 nm by using an ELX808 microplate reader (BioTeK).  17 
In vitro specificity of the MNP-anti-ferritin conjugate 18 
To test the specificity of MNP-anti-ferritin conjugates, 5XFAD and nontransgenic brain 19 
sections were incubated with the MNP-anti-ferritin nanoconjugate (2 mg/mL). Sections were 20 
then washed three times in PBS and incubated for 1hour at room temperature with a goat anti 21 
rabbit Cy3 antibody (1:200; Jackson Immunoresearch). Sections were then washed in PBS and 22 
distilled water and mounted onto polylysine coated slides (Menzel-Glaser). The slides were 23 
dried overnight and coverslipped with Mowiol. 24 
In vivo specificity of the MNP-anti-ferritin conjugate 25 
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Mice were anesthetized with a mixture of isoflurane and oxygen (1.5% isoflurane per 1 L 1 
oxygen) and homeothermy was maintained through a heated water blanket (TP 500 model, 2 
Gaymar Industries, Inc, NY, USA) set at 37 ºC. To facilitate the penetration of the MNPs 3 
through the BBB, 100 µL of a solution of mannitol (15% in PBS; Sigma) was injected into the 4 
retro-orbital sinus. Then, 15 minutes later, 150 µL (2 mg/mL) of plain MNPs or MNP anti-5 
ferritin conjugate were intravenously injected (approximately 200µg MNPs/mL blood) in the 6 
same location64. Six hours after injection of the MNPs, mice were intracardially perfused and 7 
the brains were fixed as described in the histological analysis section. To identify the presence 8 
of the MNP-anti-ferritin nanoconjugate, brain sections were incubated with a secondary anti-9 
rabbit Cy3 antibody (1:200; Jackson Immunoresearch). A monoclonal anti-dextran antibody 10 
(1:500; Stem Cell Technologies) and a secondary anti-mouse FITC antibody (1:200; Jackson 11 
Immunoresearch) were used to identify the magnetic nanoparticles. 12 
Ex vivo brain MRI 13 
Transgenic 5XFAD mice were injected with MNPs and MNP-anti-ferritin as described in the 14 
previous section. Six hours after the injection, mice were transcardially perfused with PBS 15 
followed by 4% PFA. After this process, brains were extracted and immersed in Fomblin 16 
(Solvay Solexis Inc., Thorofare, NJ) in order to provide a completely dark background around 17 
the brains being imaged. A Bruker 7T scanner Biospec 70/20 was used to perform 18 
Multiplegradient echo 3D images with the following parameters: 98µm isotropic spatial 19 
resolution, TR = 200 ms, matrix =128 × 128 × 128, 10 echoes times (TE), first = 2.7 ms with 20 
echo spacing (ES) = 3.57 ms, FA =15°, imaging time = 5hours and 7minutes. 21 
The apparent transverse relaxation time T2* was measured using the ten-echo train image sets 22 
described above in several brain regions defined by region of interest (ROI). Right and left 23 
dorsal hippocampus were manually drawn and T2* values were obtained using the 24 
quantification tool of ParaVision 5.0 (Bruker, Germany). 25 
Optical microscopy 26 
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Analyses and photography of Prussian blue or fluorescence stained samples were carried out 1 
using an inverted Leica DMIRB microscope equipped with a digital camera (Leica DC100, 2 
Nussloch, Germany). The confocal microscopy analysis was performed using a LSM 510 3 
META confocal microscope coupled to an inverted microscope Axiovert200 (Zeiss) with image 4 
capture software Zeiss ZEN 2008 sp2. 5 
Statistical analysis 6 
Results are presented as mean ± S.E.M. of at least 3 independent experiments. The data were 7 
analyzed by single factor analysis of variance followed by the post hoc Tukey´s honestly 8 
significant difference test. A significance level of p < 0.05 was chosen. STATISTICA software 9 
(StatSoft, Tulsa, OK) was utilized for all statistical tests. 10 
Safety 11 
Not applicable 12 
Abbreviations 13 
AD: Alzheimer´s disease 14 
PET: positron emission tomography 15 
MNPs: magnetic iron oxide nanoparticles 16 
MRI: magnetic resonance imaging 17 
5XFAD: transgenic mice model with five familial Alzheimer’s disease mutations 18 
PBS: phosphate buffered saline 19 
GFAP: glial fibrillary acidic protein 20 
LDH: lactate dehydrogenase 21 
MES: 2-(N-morpholino) ethanesulfonic acid 22 
BBB: blood brain barrier 23 
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DDNP: 1,1-dicyano-2-[6-(dimethylamino)naphthalene-2-yl] propene 1 
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 Figure captions 6 
Figure 1: Iron, amyloid, and ferritin accumulation in 5XFAD mice. Coronal brain sections 7 
of nontransgenic (A, C, and E) and 5XFAD transgenic (B, D, and F) mice stained with: A and 8 
B) Prussian blue to detect iron accumulation; C and D) Thioflavin S to label amyloid plaques; 9 
and E and F) an anti-ferritin antibody to detect the protein ferritin. No obvious label of any 10 
markers can be detected in nontransgenic mice, while the subiculum in 5XFAD mice showed a 11 
strong labeling for iron (arrow in B), amyloid plaques (arrow in D), and ferritin (arrow in F). 12 
Scale bars in A and B: 200 µm and in C-F: 500 µm. 13 
Figure 2: Spatial relationship between ferritin and amyloid plaques in 5XFAD mice. Serial 14 
confocal microscopy images obtained every 5 µm from the top of the section to the bottom (A 15 
through D) in the Z axis from the subiculum of a 5XFAD mouse. Coronal brain sections were 16 
labeled with an antibody anti-ferritin (red) and Thioflavin S (green) to detect the presence of 17 
ferritin and amyloid plaques, respectively. Scale bar: 25 µm.  18 
Figure 3: Cell types that accumulate ferritin in 5XFAD mice. A) Coronal brain section of a 19 
5XFAD mouse stained with an anti-ferritin antibody showing the accumulation of ferritin in the 20 
subiculum area (arrow). B) Higher magnification of the same anatomical region showing a high 21 
regional colocalization of amyloid plaques stained with Thioflavin S (green) and the anti-ferritin 22 
antibody (red). C) Sections stained with the astrocytic marker GFAP (green) showed a high 23 
number of GFAP-positive cells throughout the subiculum area with no colocalization with the 24 
ferritin-positive cells (red). D) Microglial cells in the subiculum area labeled with tomato lectin 25 
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(green) showing a high degree of colocalization (yellow) with the ferritin stain (anti-ferritin 1 
antibody in red). Scale bars in A: 500 µm; in B-D: 100 µm. 2 
Figure 4: Dot-blot assay to determine the effectiveness of the anti-ferritin antibody 3 
coupling to MNPs. One µl of A) anti-ferritin antibody used for the coupling reaction, B) MNPs 4 
functionalized with the anti-ferritin antibody, C) supernatant after the coupling reaction (anti-5 
ferritin antibody not bound to MNPs), and D) MNPs used as a negative control. Note that a very 6 
high fraction of the initial antibody present in the coupling reaction did bind to the MNPs. 7 
Figure 5: Cell viability after incubation with magnetic nanoparticles. Analysis of the 8 
viability of human neuroblastoma SH-SY5Y cells (A) and neuronal-glia mixed primary cell 9 
cultures obtained from mouse brains (B) exposed to increasing concentrations of MNPs and 10 
MNP-anti-ferritin for 72 hours, assessed by the LDH and XTT assays, respectively. No 11 
remarkable changes in cell viability were observed when cells were exposed to increasing 12 
concentrations of both types of MNPs for 72 hours. Cell viability in LDH and XTT assays was 13 
considered maximum (100%) when cells were incubated without MNPs. The number of 14 
neurons, astrocytes and microglial cells did not show any changes when primary cell cultures 15 
obtained from mouse brains were incubated with either MNPs or MNPs-anti-ferritin (C). 16 
Microfluorescence images of red fluorescent MNPs-treated cell cultures stained with anti-β-III-17 
tubulin (neurons), anti-GFAP (astrocytes) and anti-Iba1 (microglia) in green show that the 18 
nanoparticles are uptaken preferentially by microglial cells (D). Inserts in D show single 19 
staining for fluorescent MNPs (red) and microglial cells stained with anti-Iba-1 (green). Nuclei 20 
were counterstained with Hoechst (blue). Each value in the graph bars represents the mean ± 21 
SEM of n = 3 independent experiments. ANOVA followed by the post-hoc Tukey´s test 22 
revealed the absence of significant differences (p>0.05) for each group compared to untreated 23 
cells with MNPs. Scale bar in D: 50µm.   24 
Figure 6: In vitro specificity of the MNP-anti-ferritin conjugate. Coronal brain sections of 25 
5XFAD (A) and nontransgenic (E) mice were stained with an antibody anti-ferritin to determine 26 
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the accumulation of this protein in the subiculum region (boxes in A and E). Note the high 1 
accumulation of ferritin in 5XFAD brain compared to nontransgenic mice. Coronal brain 2 
sections of 5XFAD (B-D) and nontransgenic (F-H) mice, adjacent to those shown in A and E 3 
respectively, were incubated first with the nanoconjugate MNP-anti-ferritin and then with a 4 
secondary antibody-Cy3 to detect the presence of the nanoconjugate MNP-anti-ferritin stained 5 
in red (C, G). MNPs were also detected by transmitted light microscopy as black dots in 6 
5XFAD (D) and nontransgenic (H) mice. B and F show merged images of C and D, and G and 7 
H, respectively. Note the high rate of colocalization of ferritin and MNPs (B) demonstrating an 8 
optimal biofunctionalization of the particles and the absence of binding of the nanoconjugate to 9 
the nontransgenic brain sections (F-H) where no ferritin accumulation can be detected (E). 10 
Scale bars: A and E: 500 µm; B-D and F-H: 50 µm. 11 
Figure 7: In vivo specificity of the MNP-anti-ferritin conjugate in 5XFAD mice. Coronal 12 
brain section of a 5XFAD mouse showing A) the accumulation of ferritin (red) and amyloid 13 
plaques stained with Thioflavin S (green); B) the subiculum region of a 5XFAD mouse 14 
previously injected intravenously with the MNP-anti-ferritin conjugate, showing the presence of 15 
the MNP-anti-ferritin nanoconjugate (red) closely bound to amyloid plaques stained with 16 
Thioflavin S (green). Coronal sections of the subiculum of 5XFAD mice injected with the 17 
functionalized MNP-anti-ferritin nanoconjugate (C-E) and with the non-functionalized MNPs 18 
(F-H). The anti-ferritin antibody of the nanoconjugate was detected using a secondary antibody-19 
Cy3 (red) (C, F). All MNPs were detected using an anti-dextran-FITC antibody (green) (D, G). 20 
Merged images of C and D, and F and G are shown in E and H, respectively. Note the high 21 
accumulation of MNPs in the subiculum of animals injected with the nanoconjugate MNP-anti-22 
ferritin (C-E) and the absence of MNPs in the same area when non-functionalized MNPs were 23 
used (F-H). Scale bars: A and B: 100 µm; C-H: 50 µm.  24 
Figure 8: Ex vivo MRI in 5XFAD mice. Ex vivo MR images used to determine absolute T2* 25 
values (msec) in regions of interest (ROIs), which were the left and right hippocampus of 26 
5XFAD mice injected with MNPs (A) and MNPs-anti-ferritin (B). Graphic shows the data 27 
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33 
 
corresponding to the T2* value obtained in the analyzed ROIs of the left and right hippocampus 1 
in 5XFAD mice injected with MNPs versus MNP-anti-ferritin (*p < 0.05; ANOVA followed by 2 
the post-hoc Tukey´s test).  3 
 4 
 5 
 6 
 7 
 8 
 9 
 10 
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